ArticleThe pharmacogenomics journal2018
The global spectrum of protein-coding pharmacogenomic diversity.
Article in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.Clinical pharmacology and therapeutics · 2019Pooled it
- African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.EBioMedicine · 2017Pooled it
- Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans.Clinical pharmacology and therapeutics · 2026Article
- Computational variant predictors for pharmacogenomics: from evaluation of single alleles to assessment of adverse drug reactions to antidepressants.The pharmacogenomics journal · 2026Article
- Comparing self-reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models.Molecular oncology · 2025Article
- The prevalence of pharmacogenetic testing in the United States.Pharmacogenetics and genomics · 2025Article
- Opportunities and Challenges of Population Pharmacogenomics.Annals of human genetics · 2025Review
- Pharmacogenetic Profiling of Genes Associated with Outcomes of Chemotherapy in Omani Healthy Controls.Genes · 2025Article
- Pharmacogenomic landscape of TNF inhibitors in the Middle Eastern Qatari population.Frontiers in immunology · 2025Article
- Comprehensive pharmacogenomics profiling of the Serbian population.Frontiers in pharmacology · 2025Article
- Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity.iScience · 2024Article
- APF2: an improved ensemble method for pharmacogenomic variant effect prediction.The pharmacogenomics journal · 2024Article
- Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population.BMJ open diabetes research & care · 2024Article
- Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic.Pharmacogenomics · 2024Article
- Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.Clinical pharmacology and therapeutics · 2023Article
- Challenges Related to the Use of Next-Generation Sequencing for the Optimization of Drug Therapy.Handbook of experimental pharmacology · 2023Article
- Article
- Pharmacogenomic profile of a central European urban random population-Czech population.PloS one · 2023Observational
- Cytochrome P450 Transcriptional Regulation by Testis-Specific Y-Encoded-Like Protein: Identification of Novel Upstream Transcription Factors.Drug metabolism and disposition: the biological fate of chemicals · 2023Article
- A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing.Basic & clinical pharmacology & toxicology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Differences in response to medications have a strong genetic component. By leveraging publically available data, the spectrum of such genomic variation can be investigated extensively. Pharmacogenomic variation was extracted from the 1000 Genomes Project Phase 3 data (2504 individuals, 26 global populations). A total of 12 084 genetic variants were found in 120 pharmacogenes, with the majority (90.0%) classified as rare variants (global minor allele frequency <0.5%), with 52.9% being singletons. Common variation clustered individuals into continental super-populations and 23 pharmacogenes contained highly differentiated variants (F
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.